The cytokine ligands were labeled with 99mTc by a direct approach via 2-iminothiolane (2-IT) reduction at various 2-IT/protein molar ratios. In vivo inflammation targeting studies were carried out in a mouse ear edema model created by topical application of 12-O-tetradecanoyl-phorbol-13-acetate (TPA) on the right ear of ICR mice.
Radiolabeling yields increased with increasing amounts of 2-IT. When the 2-IT/protein ratio reached 1000, the radiolabeling yield was greater than 90 % without significant colloid production. TPA-treated ears showed high radioligand uptake, which was clearly detected by SPECT and autoradiographic imaging. The activities ( % ID/g) in the inflamed and control ears at 3 h after injection were 2.76 ¡À 0.20 vs. 0.69 ¡À 0.12 for IF, 5.86 ¡À 0.40 vs. 2.86 ¡À 0.61 for TF, and 7.61 ¡À 0.86 vs. 1.99 ¡À 0.31 for TFI (P < 0.05 vs. controls). TFI showed significantly higher uptake in the inflamed ears compared to TF and IF (P < 0.05). Blocking study results indicated specificity of radioligand binding with decreased radioactive uptake in the inflamed ears. Western blotting and ELISA analysis further confirmed a high expression of IL-1¦Â and TNF-¦Á in the inflamed ears.
99mTc-labeled cytokine ligands are a promising approach for detecting and understanding the inflammatory process. TFI may be more useful than the single-domain ligands for noninvasive detection of inflammatory sites.